Total Voting Rights and Share Capital as of May 13, 2024

Inventiva, a clinical-stage biopharmaceutical company, is committed to discovering and developing oral small molecule therapies aimed at addressing MASH/NASH and other diseases with high unmet medical needs. The company leverages its expertise in targeting nuclear receptors, transcription factors, and epigenetic modulation to advance its therapeutic pipeline.

As of May 13, 2024, Inventiva reported having 52,477,188 shares outstanding, with 65,493,081 gross voting rights and 65,381,630 net voting rights. These figures are crucial for calculating threshold crossings as per Article 223-11 of the AMF General Regulations. Gross voting rights include all shares with attached voting rights, even if some of these rights are suspended. Meanwhile, net voting rights exclude shares with suspended voting rights, such as treasury shares.

Inventiva’s lead product candidate, lanifibranor, is undergoing a pivotal Phase III clinical trial named NATiV3 for treating adult patients with MASH/NASH. This chronic liver disease currently lacks approved therapies, highlighting the significance of Inventiva's work in this area. Besides lanifibranor, Inventiva's pipeline features odiparcil, aimed at treating adult patients with MPS VI. However, the company has suspended clinical efforts on odiparcil to focus more on lanifibranor and is evaluating further development options for odiparcil.

Alongside these, Inventiva is also working on selecting a candidate for its Hippo signaling pathway program. The company operates with a scientific team of around 90 experts in various fields, including biology, medicinal chemistry, computational chemistry, pharmacokinetics, pharmacology, and clinical development. They have a vast library of approximately 240,000 pharmacologically relevant molecules, about 60% of which are proprietary, and a fully-owned research and development facility.

Inventiva is listed on compartment B of the Euronext Paris regulated market (ticker: IVA, ISIN: FR0013233012) and the Nasdaq Global Market in the United States (ticker: IVA).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!